AOD9604 Research Information
Growth Hormone Fragment
For Metabolic & Lipolysis Research
⚠️ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.
📑 Contents
🔬 What is AOD9604?
AOD9604 is a synthetic peptide fragment of the C-terminus of human growth hormone (Tyr-hGH177-191) that harbors the fat-reducing activity of hGH without its negative effects. It is a hexadecapeptide consisting of 16 amino acids with the sequence YLRIVQCRSVEGSCGF.
Unlike full-length growth hormone, AOD9604 does not act via IGF-1 and has no effect on insulin resistance or glucose intolerance, making it a promising research compound for metabolic studies. AOD9604 is available in pen and freeze-dried vial formulations for research purposes.
⚡ How AOD9604 Works
AOD9604 works through multiple mechanisms to influence fat metabolism:
Lipolysis
Stimulates the breakdown of fat in adipocytes
Lipogenesis Inhibition
Inhibits the transformation of non-fat materials into body fat
Non-IGF-1 Action
Does not act via IGF-1, avoiding growth hormone side effects
AOD9604 directly stimulates lipolysis and inhibits lipogenesis without affecting appetite or blood sugar levels.
📋 Research Applications
Weight Management
Investigating fat reduction and body composition in obesity research
Lipid Metabolism
Studying fatty acid oxidation and lipid regulation pathways
Cartilage & Bone
Exploring regenerative properties and cartilage repair
Metabolic Research
Investigating glucose metabolism and insulin sensitivity
📊 Clinical Studies
Phase 2b Trial (METAOD005)
- 300 obese patients received oral AOD9604 (1, 5, 10, 20 or 30 mg) or placebo daily for 12 weeks
- The 1mg dose group lost an average of 2.8 kg, more than triple the placebo group (0.8 kg)
- Rate of weight loss was maintained throughout the treatment period
Safety Profile
- No effect on serum IGF-1 levels, confirming non-IGF-1 action
- No anti-AOD9604 antibodies detected in any patients
- No negative effects on carbohydrate metabolism or insulin resistance
- Safety profile indistinguishable from placebo
💉 Interactive Dosing Guide
Select your vial size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per vial:
🖊️ Step 1: Select Your Vial Size
💊 Step 2: Select Your Dose
Vial Size
5mg Vial
Selected Dose
0.25 mg
Doses per Vial
20 doses
Pen Clicks
15 clicks
Volume
0.15 mL
Protocol Level
Level 1 (Starting)
Recommended Schedule
Daily - Loading Phase
⚠️ Do not change your dose unless advised by a qualified professional.
📋 Protocol Level Summary
Based on clinical research protocols: 0.25-2 mg daily, typically fasted in the morning.
| Protocol Level | Target Dose | Frequency | 5mg Clicks | 10mg Clicks | Who It\'s For |
|---|---|---|---|---|---|
| Level 1 (Starting) | 0.25 mg | Daily | 15 clicks | 7.5 clicks | New users, first 2 weeks |
| Level 2 (Standard) | 0.5 mg | Daily | 30 clicks | 15 clicks | After 2 weeks, maintenance |
| Level 3 (Advanced) | 1 mg | Daily | 60 clicks | 30 clicks | If more response needed |
| Level 4 (Maximum) | 2 mg | Daily | 120 clicks | 60 clicks | Experienced users only |
⚠️ Do not change your dose unless advised by a qualified professional.
💉 Vial Users (Insulin Syringe)
Add 3mL of bacteriostatic water to your freeze-dried vial and mix gently. After reconstitution, use the table below to draw your dose:
Vial Size
5mg vial with 3mL bac water
| Dose | Frequency | Units on Syringe | Volume (mL) | Protocol Level |
|---|
⚠️ Always use a new sterile needle and syringe for each injection.
⚠️ Safety & Precautions
AOD9604 has shown a very good safety and tolerability profile indistinguishable from placebo in clinical trials. It does not result in any of the adverse effects associated with full-length hGH treatment.
- No effect on serum IGF-1 levels
- No negative effects on carbohydrate metabolism or insulin resistance
- No anti-AOD9604 antibodies detected
- No dose-limiting toxicities or serious adverse events reported
Do not use if you:
- Are allergic to AOD9604 or any ingredients
- Are pregnant or breastfeeding
- Have pre-existing medical conditions (consult a healthcare professional first)
⚠️ Warning: If you experience severe allergic reactions, difficulty breathing, or signs of anaphylaxis, seek immediate medical help.
📚 References
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15.
- Herd et al. Phase 2b trial of AOD9604 in 300 obese patients. 2005.
- FDA Evaluation of AOD-9604 for 503A Bulks List. 2024.
This information is for educational and research purposes only. Always consult with a qualified healthcare professional.
Last updated: July 2026